The long standing Hematology T32 Training Grant at the University of North Carolina at Chapel Hill (UNC-CH) remains committed to training both MD physician-scientists and PhD scientists for careers in academic hematology and hematology research. This program will continue to train adult and pediatric hematology fellows and PhD post- doctoral candidates in areas of traditional institutional research strengths encompassing benign hematology. Both basic bench and clinical research tracks are available, with carefully selected didactic coursework to complement the training experience. In this competitive renewal application, scientific and educational interactions between MD and PhD trainees in the form of conferences, journal clubs, and symposia have been emphasized. Following 2 years of training on the T32 grant, trainees will be encouraged to apply for individual or institutional K series awards, and/or other sources of independent funding.
For over 35 years, the training program in academic hematology at the University of North Carolina at Chapel Hill (UNC-CH) has benefitted from support by the Ruth L. Kirschstein National Research Service Award. This program, which encompasses disorders of the blood, vasculature or immune system, has been extraordinarily successful in its mission to train clinical and bench researchers in hematology. The cornerstones of training include a mentored research project, focused seminars and conferences, training in the responsible conduct of research, and didactic coursework in clinical research, laboratory methodology, grantsmanship, and the academic community. Both MD and PhD postdoctoral candidates are recruited from intramural and extramural sources, and their frequent interaction during the 2-year period of support engenders a mutual respect and understanding of the ultimate goals of biomedical research in hematologic disorders.
|Martin, Karlyn A; Lee, Craig R; Farrell, Timothy M et al. (2017) Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. Am J Med 130:517-524|
|Houghton, Damon E; Moll, Stephan (2017) Antiphospholipid antibodies. Vasc Med 22:545-550|
|Houghton, Damon E; Sud, Shivani; Moll, Stephan et al. (2017) Perils in the thrombophilia workup: Frequency and circumstances of erroneously ordered factor V activity tests for thrombophilia. Vasc Med 22:527-528|
|Croteau, S E; Abajas, Y L; Wolberg, A S et al. (2017) Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor. Haemophilia 23:e93-e98|
|Lee, Robert H; Bergmeier, Wolfgang (2017) Sugar makes neutrophils RAGE: linking diabetes-associated hyperglycemia to thrombocytosis and platelet reactivity. J Clin Invest 127:2040-2043|
|Beckman, Joan D; Rollins-Raval, Marian A; Raval, Jay S et al. (2017) Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. Am J Ther :|
|Walton, Bethany L; Lehmann, Marcus; Skorczewski, Tyler et al. (2017) Elevated hematocrit enhances platelet accumulation following vascular injury. Blood 129:2537-2546|
|Noubouossie, Denis F; Whelihan, Matthew F; Yu, Yuan-Bin et al. (2017) In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood 129:1021-1029|
|Whelihan, Matthew F; Cooley, Brian; Xu, Yongmei et al. (2016) In vitro and in vivo characterization of a reversible synthetic heparin analog. Thromb Res 138:121-129|
|Rautou, Pierre-Emmanuel; Tatsumi, Kohei; Antoniak, Silvio et al. (2016) Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury. J Hepatol 64:53-9|
Showing the most recent 10 out of 61 publications